Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study

International Journal of Cardiology

Volumn 187, Issue 1, 2015, Pages 502-507

  Bonello, Laurent ^a,b   Frere, Corinne ^b   Cointe, Sylvie ^b   Laine, Marc ^a   Mancini, Julien ^b,c   Thuny, Franck ^a   Kerbaul, François ^a,b   Lemesle, Gilles ^d   Paganelli, Franck ^a   Guieu, Regis ^b   Arnaud, Laurent ^b,e   Dignat George, Françoise ^b,e   Sabatier, Florence ^b,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c TIMONE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Endothelial; P2y12 adp receptor; Pleiotropic; Progenitor cells; Vascular healing

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CLOPIDOGREL; PHYCOERYTHRIN; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEM CELL; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BLOOD; BODY MASS; DRUG EFFECTS; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; ANTIGENS, CD34; BODY MASS INDEX; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84929324278     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.414     Document Type: Article

References (42)

1. R.F. Storey, D.J. Angiolillo, S.B. Patil, et al., Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy, J. Am. Coll. Cardiol. 56 (2010) 1456-1462.
2. L. Wallentin, R.C. Becker, A. Budaj, et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N. Engl. J. Med. 361 (2009) 1045-1057.
3. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators, The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease, Eur. Heart J. 21 (2000) 2033-2041.
4. S.D. Wiviott, E. Braunwald, C.H. McCabe, et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes, N. Engl. J. Med. 357 (2007) 2001-2015.
5. T. Asahara, T. Murohara, A. Sullivan, et al., Isolation of putative progenitor endothelial cells for angiogenesis, Science 275 (1997) 964-967.
6. M. Hristov, C. Weber, Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance, J. Cell. Mol. Med. 8 (2004) 498-508.
7. G.J. Padfield, D.E. Newby, N.L. Mills, Understanding the role of endothelial progenitor cells in percutaneous coronary intervention, J. Am. Coll. Cardiol. 55 (2010) 1553-1565.
8. D.P. Basile, M.C. Yoder, Circulating and tissue resident endothelial progenitor cells, J. Cell. Physiol. 229 (2014) 10-16.
9. C. Schmidt-Lucke, L. Rössig, S. Fichtlscherer, et al., Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair, Circulation 111 (2005) 2981-2987.
10. N. Werner, S. Kosiol, T. Schiegl, et al., Circulating endothelial progenitor cells and cardio-vascular outcomes, N. Engl. J. Med. 353 (2005) 999-1007.
11. S. Schwartzenberg, A. Afek, G. Charach, et al., Comparative analysis of the predictive power of different endothelial progenitor cell phenotypes on cardiovascular outcome, World J. Cardiol. 2 (2010) 299-304.
12. K. Sopova, P. Tatsidou, K. Stellos, Platelets and platelet interaction with progenitor cells in vascular homeostasis and inflammation, Curr. Vasc. Pharmacol. 10 (2012) 555-562.
13. A. Vieira-de-Abreu, R.A. Campbell, A.S. Weyrich, G.A. Zimmerman, Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum, Semin. Immunopathol. 34 (2012) 5-30.
14. L. Bonello, L. Camoin-Jau, S. Arques, et al., Adjusted clopidogrel loading doses according to VASP phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study, J. Am. Coll. Cardiol. 51 (2008) 1404-1411.
15. D.R. Sutherland, L. Anderson, M. Keeney, R. Nayar, I. Chin-Yee, The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering, J. Hematother. 5 (1996) 213-226.
16. G. Davi, C. Patrono, Platelet activation and atherothrombosis, N. Engl. J. Med. 357 (2007) 2482-2494.
17. G.P. Fadini, D. Losordo, S. Dimmeler, Critical reevaluation of endothelial cell phenotype for therapeutic and diagnostic use, Circ. Res. 110 (2012) 624-637.
18. S. Massberg, I. Konrad, K. Schurzinger, et al., Platelets secrete stromal cell-derived factor 1-alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in-vivo, J. Exp. Med. 203 (2006) 1221-1233.
19. H.C. de Boer, C. Verseyden, L.H. Ulfman, et al., Endothelial progenitor cells bind and inhibit platelet function and thrombus formation, Circulation 120 (2009) 2230-2239.
20. M.L. Estes, J.A. Mund, L.E. Mead, et al., Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential, Cytometry A 77 (2010) 831-839.
21. J.S. Woo, W. Kim, H.H. Jang, J.B. Kim, W.S. Kim, K.S. Kim, Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy, Am. J. Cardiol. 113 (2014) 786-792.
22. H.C. de Boer, A.M. van Oeveren-Rietdijk, J.I. Rotmans, O.M. Dekkers, T.J. Rabelink, A.J. van Zonneveld, Activated platelets correlate with mobilization of naïve CD34(+) cells and generation of CD34(+)/KDR(+) cells in the circulation. A meta-regression analysis, J. Thromb. Haemost. 11 (2013) 1583-1592.
23. S. Fujiyama, K. Amano, K. Uehira, et al., Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells, Circ. Res. 93 (2003) 980-989.
24. N. Urao, M. Okigaki, H. Yamada, et al., Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia, Circ. Res. 98 (2006) 1405-1413.
25. L. Bonello, K. Harhouri, K. Baumstarck, et al., Mobilization of CD34+ KDR+ endothelial progenitor cells predicts target lesion revascularization, J. Thromb. Haemost. 10 (2012) 1906-1913.
26. J. George, I. Herz, E. Goldstein, et al., Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 57-60.
27. E.I. Lev, D. Leshem-Lev, A. Mager, et al., Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis, Eur. Heart J. 31 (2010) 2625-2632.
28. A. Aicher, A.M. Zeiher, S. Dimmeler, Mobilizing endothelial progenitor cells, Hypertension 45 (2005) 321-325.
29. N. Werner, S. Junk, U. Laufs, A. Link, K. Walenta, M. Bohm, G. Nickenig, Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury, Circ. Res. 93 (2003) 17-24.
30. D.H. Walter, K. Rittig, F.H. Bahlmann, et al., Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells, Circulation 105 (2002) 3017-3024.
31. D. Kong, L.G. Melo, M. Gnecchi, et al., Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries, Circulation 110 (2004) 2039-2046.
32. G. Cayla, G. Montalescot, J.P. Collet, Ticagrelor to prevent restenosis: new drug for an old hypothesis? Arterioscler. Thromb. Vasc. Biol. 30 (2010) 2320-2322.
33. L. Bonello, M. Laine, N. Kipson, et al., Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome, J. Am. Coll. Cardiol. 63 (2014) 872-877.
34. A. Wittfeldt, H. Emanuelsson, G. Brandrup-Wognsen, J.J. van Giezen, J. Jonasson, S. Nylander, L.M. Gan, Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans, J. Am. Coll. Cardiol. 61 (2013) 723-727.
35. T.H. Adair, Growth regulation of the vascular system: an emerging role for adenosine, Am. J. Physiol. 289 (2005) 283-296.
36. M.C. Montesinos,A.Desai, J.F.Chen,H. Yee, M.A. Schwarzschild, J.S. Fink, B.N. Cronstein, Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors, Am. J. Pathol. 160 (2002) 2009-1018.
37. M. Rolland-Turner, E. Goretti, M. Bousquenaud, et al., Adenosine stimulates the migration of human endothelial progenitor cells. Role of CXCR4 and microRNA-150, PLoS One 8 (2013) 54135.
38. 3 receptors are involved in the human endothelial progenitor cells migration, J. Cardiovasc. Pharmacol. 59 (2012) 397-404.
39. R.K. Dubey, D.G. Gillespie, E.K. Jackson, A2B adenosine receptors stimulate growth of porcine and rat arterial endothelial cells, Hypertension 39 (2002) 530-535.
40. J. Shen, S.P. Halenda, M. Sturek, et al., Cell-signaling evidence for adenosine stimulation of coronary smooth muscle proliferation via the A1 adenosine receptor, Circ. Res. 97 (2005) 574-582.
41. A.N. Clark, R. Youkey, X. Liu, et al., A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes, Circ. Res. 101 (2007) 1130-1138.
42. C.J. Van Dyck, V.Y. Hoymans, H. Bult, et al., Resolute and Xience V polymer-based drug-eluting stents compared in an atherosclerotic rabbit double injury model, Catheter. Cardiovasc. Interv. 81 (2013) 259-268.